Before joining Clyra, Mr. Harrison served on the Board of Directors of BioLargo, Inc. as Chairman of the Audit & Compensation committees and was an advisor for and investor in several healthcare and consumer products companies. Mr. Harrison was founder and CEO of InTouch Communications, Inc., a Competitive Local Exchange Carrier (CLEC), providing residential and business telephone services within the state of California. Mr. Harrison also served as CEO of Resource Medical Group, Inc., a provider of healthcare management consultancy services as well as President of Harrison Medical Technologies, Inc., a developer and marketer of diagnostic tests in partnership with University of California, Los Angeles.
Dr. Tanya Rhodes
Prior to joining Clyra, Dr. Rhodes served as President and CEO of Rhodes & Associates, a provider of healthcare consulting services, whose services spanned across the R&D, regulatory compliance, clinical trial, manufacturing and business development processes. She previously served as CEO of Manukamed, a developer, manufacture and marketer of products for wound healing, repair and regeneration. Dr. Rhodes served as CTO for a start-up pharmaceutical company, NitroBiotherapeutics, a developer of novel biopharma compounds. Prior to her C-Level roles, Dr. Rhodes held various management positions, including time as VP of Innovation for Smith and Nephew.
Dr. Brock Liden
Dr. Liden is a Board Certified Doctor of Podiatric Medicine in private practice. He is recognized as one of the world’s foremost experts in wound care and diabetic limb salvage. Most recently, Dr. Liden developed the SkinDiscTM technology. He has also been involved in multiple successful product development programs, including the GraftJacket, PriMatrix, and the Endoform Collagen Matrix dressing. He was integrally involved with Endoform from early clinical work, through the CMS coverage policy, and sales and marketing of the product, ultimately growing it the number 2 top-selling product in the U.S. collagen dressing market in a period of five years. Dr. Liden is a graduate of Capital University, received his Medical Degree from Ohio College of Podiatric Medicine and completed his Residency at the Dayton VA Medical Center.
Before his role at Clyra, Mr, Brown was Co-Managing partner Scion Solutions LLC. Mr. Brown Spencer has spent over 35 years in the medical device industry as an account manager, sales trainer/technician, territory manager and distributor, including stints at Zimmer and Wright Medical. As a leading distributor, Mr. Brown developed one of the first mobile labs for on-site surgeon education. Mr. Brown was co-creator of the first-to-market ‘Value Priced Orthopedic Implant’ company, White Box Orthopedics, which was sold to Microport/Implant Partners. He has several patents currently being processed or in the final review with the patent office and was also co-designer of the FastCast off-loading Total Contact System, which was taken from concept to acquisition prior to launch in 18 months. Mr. Brown holds Bachelor of Science from Purdue University.
Charles K. Dargan II
Charles K. Dargan II is the founder and President of CFO 911 Corporation, (www.cfo911.com) an organization of accounting, finance and operational experts who provide management and financial expertise to middle market private and small capitalization public companies to solve their critical accounting, finance and operational issues. CFO 911’s professionals have amassed a unique depth and breadth of operational and financial experience developed by having worked as CEOs, Presidents, COOs and CFOs of Fortune 500 firms, mid-cap and small-cap publicly traded companies, middle market and emerging growth private companies and not-for-profit organizations. Mr. Dargan has also served as the Chief Financial Officer and Chief Operating Officer of both public and private companies in a wide variety of industries including software, technology, energy, retail, leisure, securities and business services. Mr. Dargan’s public company senior management experience includes Semotus Solutions, Inc., a wireless mobility software company, BioLargo, Inc. a disinfectant and sterilization company and CPSM, Inc., a pool service, resurfacing and refurbishing company. Mr. Dargan served as a director of CPSM, Inc., Hiplink Software and Anchor Audio, Inc. Further, Mr. Dargan began his finance career in investment banking with Drexel Burnham Lambert and later became Managing Director of two regional firms, including Houlihan Lokey Howard & Zukin, where he was responsible for the management of the private placement activities of the firm. Additionally, Mr. Dargan founded and was the Chief Financial Officer of Ambient Capital, a boutique investment bank and broker dealer. Mr. Dargan received his B.A. degree in Government from Dartmouth College, his M.B.A. degree and M.S.B.A. degree in Finance from the University of Southern California and holds a CPA and CFA license
Director of Product Development
Dr. Bejarano is a researcher experienced in fundamental and applied research related to materials science, including biomaterials for regenerative medicine and multifunctional nanoparticles for controlled drug delivery. Julian has a Masters in Materials Engineering from the Universidad del Valle, Colombia and a Doctorate in Engineering Sciences with emphasis in Materials Science from the Universidad de Chile. Julian was a visiting researcher during his Ph.D. studies at the Institute of Biomaterials at the University of Erlangen-Nuremberg, Germany. Following his doctorate studies, Dr. Bejarano was a postdoctoral fellow at the Advanced Center for Chronic Diseases in Chile and Research Advisor of the Group of Polymer Engineering at the Universidad de Chile.
Corporate Regulatory Counsel
lan G. Minsk is a Partner and Leader of the Food & Drug Practice Team of Arnall Golden Gregory LLP, an Am Law 200 law firm located in Atlanta, Georgia and Washington, D.C. Mr. Minsk advises pharmaceutical, biologic, medical device, cosmetic and food companies (including dietary supplements and medical foods) on all legal and regulatory matters relating to the U.S. Food and Drug Administration. He counsels clients on a wide variety of FDA-related issues including regulatory strategies and life cycle management, combination products, FDA enforcement, FDA inspections, corporate compliance, market exclusivity, product promotion and advertising, product liability, clinical trials and imports and exports. In addition, Mr. Minsk works with life science companies and venture capital firms on regulatory diligence matters involving acquisitions, divestitures, regulatory opinion letters, co-promotions and licensing agreements. He also drafts and reviews agreements relating to clinical trials, quality, and contract manufacturing. Mr. Minsk conducts in-house training on FDA and fraud and abuse topics.
Mr. Minsk serves as general counsel of PDMA Alliance Inc., a pharmaceutical trade organization focused on compliance with the Prescription Drug Marketing Act and sample accountability. An active thought leader, Mr. Minsk has written book chapters, articles and bulletins on a wide variety of issues, including 505(b)(2) NDAs, orphan drugs, product promotion, quality agreements, compliance, and medical device regulation. He currently serves on a number of editorial boards for professional publications, including the RAPS Focus magazine, the Law Journal Newsletter's Product Liability Law and Strategy, and the Food and Law Drug Institute's Food and Drug Journal. Mr. Minsk is nationally recognized by Chambers USA for “Life Sciences: Regulatory/Compliance,” has been selected for inclusion in the international publication of Who’s Who Legal for “Life Sciences: Regulatory,” and is recognized by Best Lawyers for “FDA Law.”